A 1-year high was hit by InflaRx N.V. (NASDAQ:IFRX). Today’s price per share was $49.17. It’s 6.00 % above our $52.12. Barchart.com announced it on Apr, 17. It has $1.28B MC. At $52.12 target, the company’s valuation could be $76.62 million more.
IFRX is touching $49.17 during the last trading session, after decreased 2.74%.InflaRx N.V. has volume of 166,617 shares. Since April 17, 2018 IFRX has risen 39.39% and is uptrending. IFRX outperformed the S&P 500 by 35.02%.
For more InflaRx N.V. (NASDAQ:IFRX) news published recently go to: Globenewswire.com, Benzinga.com, Seekingalpha.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis – GlobeNewswire” published on December 19, 2018, “38 Stocks Moving In Tuesday’s Mid-Day Session – Benzinga” on April 09, 2019, “Reader Inquiry: Is InflaRx A Buy On The Dip? – Seeking Alpha” with a publish date: May 13, 2018, “InflaRx N.V. To Host R&D Day on Hidradenitis Suppurativa and its Breakthrough Anti-C5a Monoclonal Antibody IFX-1 – GlobeNewswire” and the last “Richard Brudnick to Join InflaRx Board of Directors – GlobeNewswire” with publication date: February 14, 2019.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States.The firm is worth $1.28 billion. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases.Last it reported negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.